Immune-related Pneumonitis With Nivolumab and Ipilimumab During the Coronavirus Disease 2019 (COVID-19) Pandemic

Eur J Cancer. 2020 Jun 17;135:147-149. doi: 10.1016/j.ejca.2020.06.004. Online ahead of print.

Abstract

No abstract available

Keywords: Adverse drug reactions; COVID-19; Immunotherapy; PD-1; Pneumonitis.

Publication types

  • Letter